Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Data Byte

Preclinical IPO companies don’t stay preclinical for long

Preclinical status comes with risk for IPO investors, but most of the companies enter the clinic within a few months

October 17, 2022 11:35 PM UTC

Most biotechs that are preclinical at the time of their IPO are poised to enter clinical trials quickly, finds an analysis by BioCentury.

Despite the extra risk that comes with investing in a company that has not yet entered the clinic, the number of preclinical biotechs that have gone public on NASDAQ has increased in recent years, jumping from two in 2017 to 23 in 2020...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article